Literature DB >> 25456116

Effects of dexmedetomidine on patients undergoing radical gastrectomy.

Yulan Wang1, Xuefeng Xu2, Hong Liu3, Fuhai Ji4.   

Abstract

BACKGROUND: Surgical stress may cause immunosuppression especially in patients who have surgery for primary tumor removed. This study aimed to explore the effects of dexmedetomidine on immune and inflammatory response in patients undergoing radical gastrectomy.
METHODS: After the institutional review board approval and written informed consent, forty patients undergoing radical gastrectomy were equally randomized to receive dexmedetomidine infusion (Dex group; 0.5 μg · kg(-1) initial dose followed by a maintenance dose of 0.4 μg · kg(-1) h(-1)) or normal saline infusion (NS group). Helper T lymphocytes (T helper 1 [Th1] and T helper 2 [Th2]), tumor necrosis factor-α, and interleukin-6 were measured during and after surgeries. Plasma catecholamine levels were also measured during surgery. Postoperative pain was measured by a visual analog scale.
RESULTS: The percentage of Th1 increased significantly at the end of surgery, 24 h after surgery (P = 0.045 and 0.048, respectively), and Th2 decreased notably at the end of surgery in the Dex group (P = 0.030). Plasma levels of tumor necrosis factor-α (P = 0.045 and 0.036, respectively) and interleukin-6 (P = 0.049 and 0.042, respectively) differed significantly at the end of surgery and 24 h after surgery. Plasma epinephrine and norepinephrine levels decreased significantly at the beginning of surgery in the Dex group (P = 0.020 and 0.015, respectively). At the end of surgery, plasma dopamine levels decreased significantly in the Dex group (P = 0.048), but increased in the NS group. The visual analog scale pain score was lower in the Dex group than in the NS group 24 h after surgery (P = 0.046).
CONCLUSIONS: Dexmedetomidine has been shown to reduce surgical stresses and maintain Th1/Th2 balance. It has been shown to reduce inflammatory responses and exerts immunoprotective effect.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Catecholamines; Cytokines; Dexmedetomidine; Th1/Th2; VAS

Mesh:

Substances:

Year:  2014        PMID: 25456116     DOI: 10.1016/j.jss.2014.10.008

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  8 in total

1.  Extra Loading Dose of Dexmedetomidine Enhances Intestinal Function Recovery After Colorectal Resection: A Retrospective Cohort Study.

Authors:  Guo-Zun He; Ning Bu; Ya-Juan Li; Yuan Gao; Ge Wang; Zhi-Dong Kong; Min Zhao; Shan-Shan Zhang; Wei Gao
Journal:  Front Pharmacol       Date:  2022-04-25       Impact factor: 5.988

2.  Dexmedetomidine expands monocytic myeloid-derived suppressor cells and promotes tumour metastasis after lung cancer surgery.

Authors:  Xiaosan Su; Yaodong Fan; Liu Yang; Jie Huang; Fei Qiao; Yu Fang; Jun Wang
Journal:  J Transl Med       Date:  2018-12-11       Impact factor: 5.531

3.  Effects of propofol anesthesia versus sevoflurane anesthesia on postoperative pain after radical gastrectomy: a randomized controlled trial.

Authors:  Fu-Hai Ji; Dan Wang; Juan Zhang; Hua-Yue Liu; Ke Peng
Journal:  J Pain Res       Date:  2018-06-25       Impact factor: 3.133

4.  Comparison of pectoralis plane blocks with ketamine-dexmedetomidine adjuncts and opioid-based general anaesthesia in patients undergoing modified radical mastectomy.

Authors:  Shagun B Shah; Rajiv Chawla; Akhilesh Pahade; Amit Mittal; Ajay K Bhargava; Rajeev Kumar
Journal:  Indian J Anaesth       Date:  2020-12-12

5.  Effects of Perioperative Dexmedetomidine on Immunomodulation in Uterine Cancer Surgery: A Randomized, Controlled Trial.

Authors:  Jin Sun Cho; Kieun Seon; Min-Yu Kim; Sang Wun Kim; Young Chul Yoo
Journal:  Front Oncol       Date:  2021-11-16       Impact factor: 6.244

Review 6.  Effects of Dexmedetomidine on Immune Cells: A Narrative Review.

Authors:  Rui Chen; Yan Sun; Jing Lv; Xiaoke Dou; Maosha Dai; Shujun Sun; Yun Lin
Journal:  Front Pharmacol       Date:  2022-05-02       Impact factor: 5.810

Review 7.  The Role of Dexmedetomidine in Tumor-Progressive Factors in the Perioperative Period and Cancer Recurrence: A Narrative Review.

Authors:  Qiang Cai; Guoqing Liu; Linsheng Huang; Yuting Guan; Huixia Wei; Zhiqian Dou; Dexi Liu; Yang Hu; Meiling Gao
Journal:  Drug Des Devel Ther       Date:  2022-07-06       Impact factor: 4.319

8.  Intraoperative use of dexmedetomidine is associated with decreased overall survival after lung cancer surgery.

Authors:  Juan P Cata; Vinny Singh; Brenda M Lee; John Villarreal; John R Mehran; J Yu; Vijaya Gottumukkala; Hagar Lavon; Shamgar Ben-Eliyahu
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2017 Jul-Sep
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.